Study on the material basis of efficacy of Zhenyang jiuxin decoction for the treatment of chronic heart failure
- VernacularTitle:振阳救心汤治疗慢性心力衰竭的药效物质基础研究
- Author:
Zhongkai ZHAO
1
;
Xu WANG
1
;
Jia YANG
1
;
Dantong ZHAO
2
;
Yanqiu WU
3
;
Peizhen CAO
3
;
Rong RONG
4
;
Qihui SUN
5
Author Information
1. School of Pharmacy，Shandong University of Traditional Chinese Medicine，Jinan 250355，China
2. School of Pharmacy，Shandong University of Traditional Chinese Medicine，Jinan 250355，China;Dept. of Traditional Chinese Medicine，Heze Medical College，Shandong Heze 274000，China
3. Dept. of Cardiology，Heze Hospital of Traditional Chinese Medicine，Shandong Heze 274000，China
4. School of Pharmacy，Shandong University of Traditional Chinese Medicine，Jinan 250355，China;Key Laboratory of Traditional Chinese Medicine Classical Theory，Ministry of Education，Jinan 250355，China;Shandong Key Laboratory of Digital Traditional Chinese Medicine，Jinan 250355，China
5. School of Pharmacy，Shandong University of Traditional Chinese Medicine，Jinan 250355，China;Key Laboratory of Traditional Chinese Medicine Classical Theory，Ministry of Education，Jinan 250355，China
- Publication Type:Journal Article
- Keywords:
Zhenyang jiuxin decoction;
chronic heart failure;
components in blood;
molecular network;
network pharmacology;
icariin
- From:
China Pharmacy
2026;37(13):1679-1684
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE To analyze the chemical constituents and absorbed prototype components in blood of Zhenyang jiuxin decoction， and explore its potential active substances in the treatment of chronic heart failure （CHF）. METHODS SD rats were divided into a blank group （distilled water） and administration groups with blood collection at 0， 15， 30 and 60 min after dosing （14.96 g/kg calculated by crude drug）， with 2 rats in each group. Intragastric administration was conducted once every 12 hours for 3 consecutive days. After the last administration， rat blood was collected to prepare drug-containing serum. UPLC-Q-Exactive Orbitrap HRMS combined with the Global Natural Products Social Molecular Networking technology was adopted to identify the chemical constituents of Zhenyang jiuxin decoction and the absorbed prototype components in blood in drug-containing serum. Moreover， network pharmacology， molecular docking and molecular dynamics simulation were used to predict the potential active components and action targets for CHF treatment. RESULTS A total of 116 chemical constituents were identified from Zhenyang jiuxin decoction， including flavonoids （29 species）， terpenoids （26 species）， saponins （22 species） and other compounds. Twenty absorbed prototype components in blood were detected in drug-containing serum， including icariin， ginsenoside Rg 1 and atractylenolide Ⅰ. Six key active components （icariin， ginsenoside Rg 1 ， atractylenolide Ⅰ， hexadecanamide， etc.） and six core k ey targets such as glycogen synthase kinase-3β （GSK-3β）， amyloid precursor protein （APP） and epidermal growth factor receptor （EGFR） were screened out via network pharmacology. Molecular docking results showed that all key active components had favorable binding activity with core targets； among them， icariin had the strongest binding capacity to APP. Molecular dynamics simulation verified that the complex formed by icariin and APP possessed excellent stability. CONCLUSIONS The potential active substances of Zhenyang jiuxin decoction against CHF are icariin， ginsenoside Rg₁， atractylenolide Ⅰ and other ingredients， which act on APP， EGFR， GSK-3β and other targets. APP may serve as one of the important action targets of icariin.
